Various symptoms indicate chronic myelogenous leukemia (CML) has progressed from one phase to another. These include an increase in leukemia cells, a change in a person’s platelet count, and worsening ...

Newly published data suggests most patients are opting for second- or third-generation tyrosine kinase inhibitors instead of a generic form of imatinib. Patients with chronic myelogenous leukemia (CML ...

Chronic myelomonocytic leukemia (CMML) and chronic myeloid leukemia (CML) are two types of cancers that affect the blood and bone marrow. In both types, certain blood cells multiply out of control.

An advocate discusses vital patient-provider conversations to promote the best care for individuals with chronic myeloid leukemia. Receiving a diagnosis of chronic myeloid leukemia (CML) can be ...

Initial discussions about treatment, side effects and study results can help patients navigate through all aspects of a chronic myeloid leukemia diagnosis. The initial discussions with health care ...

The life expectancy of patients with recently diagnosed chronic myeloid leukemia (CML) is now approaching that of the general population, which is an important message for physicians to convey to ...

Please provide your email address to receive an email when new articles are posted on . It has been eight years since imatinib was approved as the first oral tyrosine kinase inhibitor indicated for ...

The case is believed to be just the second reported in the scientific literature. In patients with chronic myelogenous leukemia (CML), patients sometimes present with soft-tissue hematomas resulting ...

LONDON--(BUSINESS WIRE)--The global chronic myelogenous leukemia (CML) therapeutics market size is poised to grow by USD 1.74 billion during 2019-2023, according to a new report by Technavio, ...